Recordati S.p.A was founded in 1926 by Giovanni Recordati, a pharmacist and entrepreneur who started his own laboratory in Milan. The company's headquarters are located in Milan, Italy, but it has operations in more than 40 countries across Europe, North America, Asia, Africa, and Latin America.

Recordati S.p.A produces and markets innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas such as cardiovascular, urological, gastroenterological, metabolic, and rare diseases. The company's product portfolio includes original drugs such as Zanidip®, Zanipress®, Lercanidipine Generics, Urorec®, Procto-Glyvenol®, Silodyx®, Reagila®, Isturisa®, and many others. The company also has a dedicated business unit for rare diseases, which offers treatments for conditions such as Cushing's syndrome, acromegaly, hyperammonemia, hereditary angioedema, and others.

Recordati S.p.A has a strong commitment to research and development of new specialties, with a focus on rare diseases. In 2022, the company invested € 156.5 million in R&D, representing 8.4% of its revenue. The company's market capitalization as of May 13th, 2023 was € 9.8 billion, making it one of the largest pharmaceutical companies in Italy and Europe.

Recordati S.p.A's vision is to be a global leader in providing high-quality medicines that improve the health and well-being of people around the world. The company has received several awards and recognitions for its performance, innovation, and social responsibility. For example, in 2022 it was ranked among the top 10 best employers in Italy by Forbes magazine.

Foundation: 1926

Headquarters: Milan, Italy

Website: https://www.recordati.com/en/

AGC Biologics was founded in 2017 as a result of the merger between Asahi Glass Co., Ltd. and CMC Biologics. The company has its headquarters in Milan and operates a state-of-the-art manufacturing facility in Bresso. AGC Biologics has a market cap of about $8.7B and employs over 1,000 people worldwide.

AGC Biologics' vision is to be a leading global partner for the development and production of biopharmaceuticals, offering innovative solutions and high-quality services to its clients. The company specializes in mammalian and microbial expression systems, providing a full range of services from cell line development to commercial manufacturing. AGC Biologics has a diverse portfolio of products, including monoclonal antibodies, recombinant proteins, vaccines, gene therapies, and biosimilars.

One of the recent projects that AGC Biologics is involved in is the development of a COVID-19 vaccine candidate in collaboration with ReiThera, a biotech company based in Rome. The vaccine candidate uses a viral vector platform and has shown promising results in preclinical and clinical trials. AGC Biologics is responsible for the scale-up and production of the vaccine at its Bresso site.

AGC Biologics is a company that is committed to delivering excellence and value to its customers, partners, and stakeholders. It is also a company that is constantly evolving and adapting to the changing needs and demands of the biopharmaceutical industry.

Foundation: 2017
Headquarters: Milan, Italy
Website: https://www.agcbio.com/

Chiesi Farmaceutici S.p.A is a pharmaceutical company based in Parma, Italy. It was founded in 1935 by Giacomo Chiesi, a pharmacist who started his own laboratory to produce medicines for local patients. Today, the company is still owned and managed by the Chiesi family and has grown to become one of the largest and most innovative pharmaceutical companies in Italy and Europe.

RChiesi Farmaceutici S.p.A specializes in the research, development, production, and marketing of medicines for respiratory, cardiovascular, neonatal, and rare diseases. The company has a strong presence in over 80 countries, with 29 affiliates and 6 production sites. On May 13th, 2023, the company reported a market cap of $8.4B.

Chiesi Farmaceutici S.p.A has a vision to improve the quality of life of patients and their families through innovative and sustainable solutions. The company invests heavily in research and development, with more than 20% of its revenue dedicated to R&D activities. The company also collaborates with academic institutions, biotech companies, and patient organizations to foster scientific excellence and social responsibility.

Chiesi Farmaceutici S.p.A has received several awards and recognitions for its achievements and contributions to the pharmaceutical industry and society. In 2020, the company was ranked among the top 10 best workplaces in Italy by Great Place to Work Institute. The company also received the European Responsible Care Award for its commitment to environmental sustainability and social impact.

Foundation: 1935
Headquarters: Parma, Italy
Website: https://www.chiesi.com/

DiaSorin S.p.A was founded in 1968 in Italy and has its headquarters in Saluggia, a small town in the province of Vercelli. The company specializes in the immunodiagnostics and molecular diagnostics segments, which are used to detect and measure specific molecules or antigens in biological samples.

The company has a wide range of products and projects that cover various clinical areas, such as infectious diseases, endocrinology, oncology, autoimmunity, bone and mineral metabolism, and cardiovascular diseases. Some of their most innovative products include LIAISON ® XS, a fully automated system for immunochemistry tests, and LIAISON ® MDX, a platform for molecular diagnostics based on real-time PCR technology.

DiaSorin S.p.A has a strong presence in the global market, with 22 branches and offices across 5 continents and 5 manufacturing sites around the world. The company has a market cap of about $7.6B as of May 2023 and employs more than 2,000 people worldwide.

The vision of DiaSorin S.p.A is to be the diagnostic specialist that provides reliable, innovative, and standardized solutions for clinical laboratories and patients. The company is committed to investing in research and development, using its distinctive expertise in the field to deliver a high level of innovation. The company has also received several awards and recognitions for its excellence in quality, sustainability, and social responsibility.

Foundation: 1968

Headquarters: Saluggia, Vercelli, Italy

Website: https://www.diasorin.com/home/

Dompé Farmaceutici S.p.A is a biopharmaceutical company based in Italy. The company was founded in 1940 by Alberto Dompé, a pharmacist and entrepreneur who wanted to improve the quality of life of patients through science and technology. Today, Dompé is led by his grandson, Sergio Dompé, who shares the same vision and passion for making a difference in healthcare.

Dompé has its headquarters in Milan, Italy, and operates in several countries around the world, including the US, Canada, China, Albania, and Switzerland. The company has a market cap of about $2.4B as of May 2023 and employs more than 800 people, most of whom are scientists and researchers.

Dompé's product portfolio includes drugs for primary and specialty care, such as diabetes, cardiovascular diseases, ophthalmology, and dermatology. The company also has a strong pipeline of projects in the fields of nerve growth factor (NGF), gene therapy, and artificial intelligence. One of its most promising projects is Exscalate, a platform that uses supercomputers and machine learning to design new drugs for various diseases, including COVID-19.

Dompé has received several awards and recognitions for its achievements and contributions to the biopharmaceutical industry. In 2021, the company was ranked among the top 10 most innovative companies in Europe by Fast Company magazine. In 2022, Dompé was awarded the European Biotech Leadership Award by Euronext for its outstanding performance and growth. In 2023, Dompé was named one of the World's Best Employers by Forbes magazine for its culture of innovation and diversity.

Foundation: 1940

Headquarters: Milan, Italy

Website: https://www.dompe.com/

Arterra Bioscience is a biotechnology company based in Naples, Italy, that specializes in the discovery and development of natural bioactive compounds for various applications in health, nutrition, cosmetics, and agriculture. Founded in 2003 by Dr. Adriana Albini, a renowned scientist, and entrepreneur, Arterra Bioscience has grown to become one of the most innovative and successful biotech companies in Italy and Europe.

Arterra Bioscience has a strong vision of creating a sustainable and circular bioeconomy, where natural resources are used efficiently and responsibly to produce high-value products that improve human well-being and environmental quality. To achieve this vision, Arterra Bioscience employs cutting-edge technologies such as genomics, metabolomics, bioinformatics, and bioprocessing to explore the vast diversity of microorganisms and plants and identify novel molecules with beneficial properties.

Arterra Bioscience has a diversified portfolio of products and projects that address various market needs and challenges. Some of the products include Arteris®: a patented formulation of natural antioxidants derived from olive leaves that protects the skin from oxidative stress and aging, Arterol®: a natural dietary supplement that lowers cholesterol levels and reduces cardiovascular risk, Arterin®: a natural anti-inflammatory agent that modulates the immune system and alleviates chronic inflammatory diseases and Arterix®: a natural insect repellent that protects humans and animals from mosquito-borne diseases.

Arterra Bioscience has received several awards and recognitions for its excellence and innovation in biotechnology. In 2018, Dr. Adriana Albini was awarded the EU Prize for Women Innovators, one of the most prestigious awards in Europe for female entrepreneurs. In 2020, Arterra Bioscience was ranked among the top 10 biotech companies in Italy by BioSpace, a leading online platform for biotech news and careers.

Foundation: 2003
Headquarters: Naples, Italy
Website: https://arterrabio.it/

Genenta Science was founded in 2015 by Ospedale Raffaele Hospital (OSR), Milan, Pierluigi Paracchi, Luigi Naldini, and Bernhard Gentner. The company is a spin-off of the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), a world-leading cell and gene therapy research institution.

Genenta Science's product and project is Temferon™, a cell-based platform that harnesses the power of hematopoietic stem cells to deliver an immunotherapeutic payload within tumors, where it can direct the natural immune responses towards malignant cells. Temferon™ is not tumor type nor target antigen restricted and provides a sustained targeted expression of therapeutic payload(s) inside the tumor microenvironment. Genenta Science plans to expand its pipeline to other hard-to-treat cancer types in the future.

Genenta Science's vision is to provide durable and safe treatments for solid tumors, which are often resistant to conventional therapies such as chemotherapy, radiation, and immunotherapy. The company aims to develop Temferon™ as a one-time monotherapy, but also as a potential combination therapy with other approved therapeutics.

Genenta Science's market cap is $1.7B in May 2023. The company has also received several awards and recognitions, such as being selected as one of the 50 most innovative companies in Italy by Wired magazine in 2019.

Foundation: 2015

Headquarters: Milano, Italy

Website: https://www.genenta.com/

Philogen S.p.A. was founded in 1996 and is listed on the Italian Stock Exchange. The company's headquarters are in Siena, Italy, and it has a subsidiary named Philochem near Zurich, Switzerland, where research activities are performed. The company's market cap as of May 2023 is $1.6B.

The company's strategy is to deliver bioactive agents to the site of disease using antibodies or small organic ligands, thus increasing the therapeutic activity and helping spare normal tissues. It has generated a strong proprietary pipeline of clinical-stage products for various indications, such as solid tumors, rheumatoid arthritis, psoriasis, and infectious diseases.

Philogen S.p.A.'s product portfolio includes Darleukin (L19-IL2), Fibromun (L19-TNF), L19-FAP (L19-FAP), Nidlegy (L19-IL2/L19-TNF), and Vesanoid (L19-RARa). Its projects include collaborations with academic institutions, such as ETH Zurich and the University of Zurich, and pharmaceutical companies, such as Pfizer, Novartis, Boehringer Ingelheim, and Servier .

Philogen is also involved in several research projects and collaborations with academic and industrial partners. For example, Philogen is part of the Horizon 2020 project PHOENIX, which aims to develop novel nanomedicines for cancer immunotherapy. Philogen also received the European Innovation Award in 2019 for its contribution to the field of biotechnology.

Philogen S.p.A. has received several awards and recognitions for its scientific excellence and innovation, such as the Swiss Technology Award in 2004 and 2010, the Prix Galien Italia in 2010 and 2018, the European Inventor Award in 2019, and the Swiss Biotech Success Stories Award in 2020.

Foundation: 1996
Headquarters: Siena, Italy

Website: https://www.philogen.com/

Newron Pharmaceuticals S.p.A was founded in 1999 and is headquartered in Bresso, near Milan, Italy. It also has a subsidiary in Morristown, NJ, USA. The company has a market cap of about $1.5B as of May 2023 and is listed on the SIX Swiss Exchange, the primary market of the Düsseldorf Stock Exchange, and on XETRA.

Newron Pharmaceuticals S.p.A's vision is to deliver innovative treatments to improve the quality of life for patients with CNS disorders. It has a strong pipeline of promising treatments, including one marketed product and wholly-owned product candidates in clinical development.

Newron Pharmaceuticals S.p.A's product is Xadago®, a once-daily oral medication for Parkinson's disease that was approved by the European Commission in 2015 and by the US Food and Drug Administration in 2017. It is also approved in several other countries, such as Japan, Australia, Canada and Brazil.

The company's main project is Evenamide, a potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. It is currently in phase III clinical trials and has received Fast Track designation from the US FDA. Newron Pharmaceuticals S.p.A's other project is ralfinamide, a sodium channel blocker for patients with specific rare pain indications, such as lumbosacral radicular pain and neuropathic pain associated with Fabry disease. It is currently in phase II clinical trials.

Foundation: 1999

Headquarters: Bresso, Italy

Website: https://www.newron.com/

Molteni Farmaceutici S.p. was founded in 1892 by Giuseppe Molteni, a pharmacist, and entrepreneur who wanted to produce and distribute innovative medicines. The company is still family-owned and has its headquarters in Florence, Italy. According to its website, Molteni Farmaceutici S.p.A has a market cap of about $1.4B in May 2023 and employs more than 800 people.

The vision of Molteni Farmaceutici S.p.A is to improve the quality of life of patients by offering effective and safe solutions for their health needs. The company focuses on three main therapeutic areas: pain management, addiction treatment, and rare diseases. Some of the products that Molteni Farmaceutici S.p.A include opioids, naloxone, methadone, buprenorphine, and naltrexone.

Molteni Farmaceutici S.p.A is also involved in several research and development projects, both internally and in collaboration with other partners. For example, the company is working on a new formulation of naloxone for intranasal administration, which could be used to reverse opioid overdose more quickly and easily. Another project is the development of gene therapy for hemophilia A, a rare bleeding disorder caused by a lack of factor VIII.

Molteni Farmaceutici S.p.A has received several awards and recognitions for its achievements and contributions to the pharmaceutical industry. In 2019, the company won the Best Managed Companies award from Deloitte, which honors excellence in strategy, skills, innovation, culture, and governance. In 2020, the company was ranked among the top 100 Italian companies for sustainability by Il Sole 24 Ore, a leading business newspaper in Italy.

Foundation: 1892
Headquarters: Florence, Italy
Website: https://www.moltenifarma.it/